Seres Therapeutics, Inc.
MCRBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MCRB. That does not mean none is planned.
Get an email about MCRB's next catalysts
Track Seres Therapeutics (MCRB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
MCRB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.34 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SER-109 | Phase 3 | Clostridium Difficile Infection | - | - |
Clostridium Difficile Infection
1 drug in this indication
Clostridium Difficile
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Seres Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Seres Therapeutics, Inc.'s (MCRB) pipeline across Phase 3. Its lead program is SER-109 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seres Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Seres Therapeutics, Inc. (MCRB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MCRB biotech catalysts?→
Add MCRB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seres Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.